QQQ   431.64 (+0.13%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
QQQ   431.64 (+0.13%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
QQQ   431.64 (+0.13%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
QQQ   431.64 (+0.13%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
Free Trial
NASDAQ:VIE

Viela Bio (VIE) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)
Free VIE Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$53.01
▼
$53.01
50-Day Range
$52.92
▼
$53.20
52-Week Range
$25.02
▼
$65.00
Volume
N/A
Average Volume
1.07 million shs
Market Capitalization
$2.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
VIE stock logo

About Viela Bio Stock (NASDAQ:VIE)

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

VIE Stock News Headlines

January 29, 2024 | benzinga.com
ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment
January 27, 2024 | bizjournals.com
ArriVent Biopharma issues upsized $175M IPO, becomes region's first life sciences firm to go public in 2024
April 16, 2024 | Paradigm Press (Ad)
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
January 9, 2024 | seekingalpha.com
ArriVent Biopharma Seeks $100 Million IPO For Lung Cancer Drug
January 5, 2024 | marketwatch.com
ArriVent BioPharma Files For IPO
December 6, 2023 | finance.yahoo.com
Myasthenia Gravis Treatment Market Size, Share & Growth Analysis, [2028] | With CAGR of 7.5%
November 17, 2023 | benzinga.com
Global CD19 Antibody Market and Clinical Pipeline Outlook and Competitive Landscape: Insight on 30 Key Players
November 9, 2023 | uk.finance.yahoo.com
Global CD19 Antibody Market Projected to Exceed $10 Billion by 2028, Driven by Promising Pipeline of Therapies
April 16, 2024 | Paradigm Press (Ad)
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
November 3, 2023 | finance.yahoo.com
Global CD19 Antibody Market Set to Surpass $10 Billion by 2028: A Revolutionary Era in Immunotherapy
October 25, 2023 | bizjournals.com
Amgen’s layoffs won’t affect Horizon Therapeutics’ Rockville footprint — for now
October 23, 2023 | finanznachrichten.de
Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
September 20, 2023 | usatoday.com
Inside 'Elon Musk': Wild details from revealing Walter Isaacson biography
July 26, 2023 | nypost.com
I’m an AI influencer: Followers crave my sexy snaps — but I don’t exist
May 8, 2023 | marketwatch.com
2023 Cutaneous Lupus Erythematosus (CLE) Treatment Market: Latest Technology Innovations and Comprehensive Growth Insights by 2031
May 5, 2023 | marketwatch.com
Cutaneous Lupus Erythematosus (CLE) Treatment Market: Opportunities for Industry Expansion in 2030
May 5, 2023 | marketwatch.com
8-K: Horizon Therapeutics Public Ltd Co
March 27, 2023 | bizjournals.com
ArriVent Biopharma raises $155M in one of largest local funding rounds of 2023
March 9, 2023 | marketwatch.com
Cutaneous Lupus Erythematosus (CLE) Treatment Market Application, Product, Sales and Forecast 2023-2028
February 10, 2023 | marketwatch.com
Exploring the Challenges and Opportunities in the Cutaneous Lupus Erythematosus (CLE) Treatment Market (2023-2028)
January 20, 2023 | marketwatch.com
Neuromyelitis Optica Spectrum Disorder (NMOSD) Market is Set to Grow in forecast period 2029
December 13, 2022 | bizjournals.com
With Horizon acquisition, Amgen would enter Montgomery County for the first time. Here’s what we know.
December 1, 2022 | bizjournals.com
Horizon Therapeutics spells out vision for Rockville R&D hub
November 16, 2022 | bizjournals.com
Life sciences firm MilliporeSigma doubling down on MoCo with $286M investment
November 15, 2022 | seekingalpha.com
SBI Holdings, Inc. (SBHGF) Q2 2023 Earnings Call Transcript
November 2, 2022 | msn.com
Why Horizon Therapeutics' Shares Rose 11.32% on Wednesday
October 21, 2022 | marketwatch.com
Cutaneous Lupus Erythematosus (CLE) Treatment Market Size, Sales, CAGR And Competition Data from 2022 To 2028
See More Headlines
Receive VIE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viela Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2021
Today
4/16/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VIE
CUSIP
N/A
CIK
N/A
Web
www.vielabio.com
Phone
240 558 0038
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($7.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-86,430,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-33.97%
Return on Assets
-31.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
19.51
Quick Ratio
19.49

Sales & Book Value

Annual Sales
$50 million
Price / Sales
58.26
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.14 per share
Price / Book
7.42

Miscellaneous

Outstanding Shares
54,950,000
Free Float
N/A
Market Cap
$2.91 billion
Optionable
Not Optionable
Beta
0.43
These 7 Stocks Will Be Magnificent in 2024 Cover
These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Zhengbin Yao (Age 55)
    Chairman, Pres & CEO
    Comp: $846.75k
  • Mr. Mitchell Chan (Age 40)
    Chief Financial Officer
    Comp: $420.34k
  • Dr. Jörn Drappa M.D. (Age 56)
    Ph.D., Chief Medical Officer and Head of R&D
    Comp: $637.39k
  • Mr. James Paul Kastenmayer J.D. (Age 49)
    Ph.D., Gen. Counsel & Company Sec.
  • Ms. Kate Surdez
    Sr. VP & Head of HR
  • Ms. Rachel Ettinger
    Sr. Director & Head of Research
  • Mr. Bill Rees
    Sr. Director & Head of Translational Science
  • Mr. Ted Phillips
    VP & Head of Clinical Operations
  • Mr. Dewei She
    Sr. Director and Head of Biostatistics, Data Management, & Programming
  • Mr. Lee Levin
    Sr. Director & Head of Quality

Key Competitors

View All Competitors

VIE Stock Analysis - Frequently Asked Questions

How were Viela Bio's earnings last quarter?

Viela Bio, Inc. (NASDAQ:VIE) announced its earnings results on Sunday, February, 28th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.10. The firm earned $9.34 million during the quarter, compared to analyst estimates of $5.10 million.

When did Viela Bio IPO?

Viela Bio (VIE) raised $150 million in an initial public offering on Thursday, October 3rd 2019. The company issued 7,500,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Guggenheim Securities was co-manager.

This page (NASDAQ:VIE) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency